BiotechTube

Onasemnogene Abeparvovec-xioi

Phase 3Completed
3 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SMA - Spinal Muscular Atrophy

Conditions

SMA - Spinal Muscular Atrophy, Gene Therapy

Trial Timeline

Oct 24, 2017 → Nov 12, 2019

NCT ID
NCT03306277

About Onasemnogene Abeparvovec-xioi

Onasemnogene Abeparvovec-xioi is a phase 3 stage product being developed by Novartis for SMA - Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03306277. Target conditions include SMA - Spinal Muscular Atrophy, Gene Therapy.

What happened to similar drugs?

7 of 20 similar drugs in SMA - Spinal Muscular Atrophy were approved

Approved (7) Terminated (1) Active (12)
🔄Ropivacaine + BupivacaineAstraZenecaPhase 3
🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3
✅Onasemnogene Abeparvovec-brveNovartisApproved
🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3
🔄onasemnogene abeparvovecNovartisPhase 3
🔄onasemnogene abeparvovec-xioiNovartisPhase 3
✅RisdiplamRocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT04042025Phase 3Active
NCT03837184Phase 3Completed
NCT03461289Phase 3Completed
NCT03505099Phase 3Completed
NCT03381729Phase 1Terminated
NCT03306277Phase 3Completed
NCT03421977Pre-clinicalActive

Competing Products

20 competing products in SMA - Spinal Muscular Atrophy

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
36
ElezanumabAbbViePre-clinical
30
Elezanumab + PlaceboAbbViePhase 2
35
Ropivacaine + BupivacaineAstraZenecaPhase 3
40
Onasemnogene Abeparvovec-xioiNovartisPhase 1
21
ZolgensmaNovartisPre-clinical
33
BVS857 + PlaceboNovartisPhase 2
35
AVXS-101NovartisPhase 1
29
Onasemnogene Abeparvovec-xioiNovartisPhase 3
44
Onasemnogene Abeparvovec-brveNovartisApproved
50
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
30
branaplamNovartisPhase 1/2
32
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
onasemnogene abeparvovecNovartisPhase 3
47
onasemnogene abeparvovec-xioiNovartisPhase 3
40
RisdiplamRochePhase 1
29
ATI355NovartisPhase 1
29